Kang TY et al. - In a retrospective review of 27 pts with recurrent or progressive high-grade gliomas, it was found that the combination of irinotecan and bevacizumab improves the outcome in progressive high-grade gliomas when compared with historical results. While the rate of severe toxicities is consistent with prior reports and mandates careful selection of pts, asymptomatic, stable intracranial blood products or hemorrhage is not an absolute contraindication to therapy Methods
Pts with at least 1 prior chemotherapy regimen were included
Pts with prior irinotecan or bevacizumab were excluded
Outcomes were analyzed on an intention-to-treat basis and estimated by the Kaplan–Meier method
Results
Median age was 46 years and median number of prior therapies was 2
18 of 27 pts have progressed, and 11 pts have died at time of analysis
Progression-free survival at 6 months is 46% and overall survival (OS) at 6 months is 84% with a median OS of 12.6 months
Of 12 pts with pretreatment radiographic evidence of intracranial hemorrhage, only 1 developed symptomatic progression of hemorrhage that required termination of therapy
See all
